Stock Track | 10x Genomics Plummets 8.52% Intraday After Q1 Report Shows Revenue Decline and License Revenue Plunge

Stock Track05-08 22:13

10x Genomics, Inc. (TXG) experienced a significant intraday plummet of 8.52% on Friday, as investors reacted to the company's latest quarterly financial results.

The sharp decline followed the release of 10x Genomics' first-quarter earnings report, which showed revenue falling 3% year-over-year to $150.84 million. While the company's adjusted loss of 10 cents per share beat analyst expectations, the revenue decline and a dramatic 94% plunge in license and royalty revenue to just $947,000 appear to have concerned investors. The mixed results, with revenue decreasing despite cost controls and margin improvements, triggered selling pressure during the trading session.

Analyst reactions to the earnings were mixed, with Piper Sandler maintaining a Hold rating and $20 price target on the stock, while Deutsche Bank raised its price target from $17 to $23. The contrasting analyst views and the underlying revenue challenges highlighted in the quarterly report contributed to the stock's volatility during Friday's trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142214710?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 22:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142214710","market":"nz","top_or_hot":-1,"title":"Stock Track | 10x Genomics Plummets 8.52% Intraday After Q1 Report Shows Revenue Decline and License Revenue Plunge","media":"Stock Track","content":"<p>10x Genomics, Inc. (TXG) experienced a significant intraday plummet of 8.52% on Friday, as investors reacted to the company's latest quarterly financial results.</p><p>The sharp decline followed the release of 10x Genomics' first-quarter earnings report, which showed revenue falling 3% year-over-year to $150.84 million. While the company's adjusted loss of 10 cents per share beat analyst expectations, the revenue decline and a dramatic 94% plunge in license and royalty revenue to just $947,000 appear to have concerned investors. The mixed results, with revenue decreasing despite cost controls and margin improvements, triggered selling pressure during the trading session.</p><p>Analyst reactions to the earnings were mixed, with Piper Sandler maintaining a Hold rating and $20 price target on the stock, while Deutsche Bank raised its price target from $17 to $23. The contrasting analyst views and the underlying revenue challenges highlighted in the quarterly report contributed to the stock's volatility during Friday's trading.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 10x Genomics Plummets 8.52% Intraday After Q1 Report Shows Revenue Decline and License Revenue Plunge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 10x Genomics Plummets 8.52% Intraday After Q1 Report Shows Revenue Decline and License Revenue Plunge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 22:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>10x Genomics, Inc. (TXG) experienced a significant intraday plummet of 8.52% on Friday, as investors reacted to the company's latest quarterly financial results.</p><p>The sharp decline followed the release of 10x Genomics' first-quarter earnings report, which showed revenue falling 3% year-over-year to $150.84 million. While the company's adjusted loss of 10 cents per share beat analyst expectations, the revenue decline and a dramatic 94% plunge in license and royalty revenue to just $947,000 appear to have concerned investors. The mixed results, with revenue decreasing despite cost controls and margin improvements, triggered selling pressure during the trading session.</p><p>Analyst reactions to the earnings were mixed, with Piper Sandler maintaining a Hold rating and $20 price target on the stock, while Deutsche Bank raised its price target from $17 to $23. The contrasting analyst views and the underlying revenue challenges highlighted in the quarterly report contributed to the stock's volatility during Friday's trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXG","symbol_name":"10x Genomics, Inc.","start_time":0,"source_url":"","article_id":"1142214710","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142214710","pubTimestamp":1778249613,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"10x Genomics, Inc. (TXG) experienced a significant intraday plummet of 8.52% on Friday, as investors reacted to the company's latest quarterly financial results.The sharp decline followed the release...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TXG":"10x Genomics, Inc."},"translate_title":"个股追踪|10x Genomics盘中暴跌8.52%，此前Q1报告显示营收下滑，授权收入暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXG":1},"content_text":"10x Genomics, Inc. (TXG) experienced a significant intraday plummet of 8.52% on Friday, as investors reacted to the company's latest quarterly financial results.The sharp decline followed the release of 10x Genomics' first-quarter earnings report, which showed revenue falling 3% year-over-year to $150.84 million. While the company's adjusted loss of 10 cents per share beat analyst expectations, the revenue decline and a dramatic 94% plunge in license and royalty revenue to just $947,000 appear to have concerned investors. The mixed results, with revenue decreasing despite cost controls and margin improvements, triggered selling pressure during the trading session.Analyst reactions to the earnings were mixed, with Piper Sandler maintaining a Hold rating and $20 price target on the stock, while Deutsche Bank raised its price target from $17 to $23. The contrasting analyst views and the underlying revenue challenges highlighted in the quarterly report contributed to the stock's volatility during Friday's trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142214710","isCrawlerRequest":true}